Krystal Biotech (NASDAQ:KRYS) Sets New 1-Year High Following Analyst Upgrade

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) reached a new 52-week high during trading on Saturday after TD Cowen raised their price target on the stock from $202.00 to $306.00. TD Cowen currently has a buy rating on the stock. Krystal Biotech traded as high as $267.48 and last traded at $261.41, with a volume of 349859 shares trading hands. The stock had previously closed at $248.91.

A number of other research analysts have also recently commented on KRYS. Guggenheim set a $224.00 target price on Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. Chardan Capital boosted their price objective on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday. Zacks Research upgraded Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $260.50.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.70% of the stock is owned by insiders.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of KRYS. Edgestream Partners L.P. acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at about $2,705,000. State of New Jersey Common Pension Fund D lifted its holdings in Krystal Biotech by 45.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock valued at $2,066,000 after purchasing an additional 4,682 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Krystal Biotech by 46.7% during the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after purchasing an additional 29,915 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after purchasing an additional 365,304 shares during the period. Finally, Tempus Wealth Planning LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth about $327,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 5.0%

The firm’s 50-day moving average is $227.55 and its two-hundred day moving average is $182.91. The stock has a market cap of $7.58 billion, a price-to-earnings ratio of 39.19 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The company had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. On average, analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.